Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Shares Rise on Acquisition Rumors

NEW YORK (GenomeWeb News) – Shares of Qiagen rose around 6 percent in Friday trade on the Nasdaq after rumors circulated in Europe that French drugmaker Sanofi-Aventis was mulling a €14.50 ($20.29) per share bid to acquire the firm.

Neither firm would comment on the rumors.

The rumored acquisition price represents a 26 percent premium over Qiagen's Thursday closing price of $16.05. In Friday afternoon trade, Qiagen's shares were up 6 percent at $17.01.

In a research note published this morning, Thomas Weisel Partners analyst Peter Lawson said that the Paris-based pharmaceuticals and vaccine giant is an "unlikely suitor" for Qiagen.

"[I]f the bid is true, we would expect it to attract other bidders from Pharma," he wrote. "However, we would reiterate that Sanofi seems an unlikely acquirer with no footprint in the life sciences space."

Qiagen's primary focus is on the sample preparation and molecular diagnostics markets, two areas in which Sanofi-Aventis does not have a presence.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.